The Hidden Problem in Today’s Cardiovascular Guidelines — They Were Built for Framingham, Not for Latinos.

Cardiovascular guidelines are supposed to protect everyone. But the math behind them wasn’t built for everyone.

For decades, the backbone of cardiovascular risk prediction—and therefore the backbone of treatment guidelines—has been the Framingham Heart Study, a landmark but deeply limited cohort drawn from a small, overwhelmingly Anglo-Saxon town in Massachusetts. Do not get me wrong. It is a beautifully crafted study spanning three generations since 1948.

But that foundation shapes the guidelines we still use today. And it leaves Hispanic/Latino adults at a disadvantage.

The Framingham Problem: A Universal Tool Built from a Non-Universal Population.

Framingham gave us the concept of “risk factors,” the 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk model, and the logic that drives statin initiation, blood pressure thresholds, and preventive care.

But Framingham was:

• Almost entirely non-Latino White.

• Socioeconomically stable.

• Culturally homogeneous.

• Not representative of the largest minority group in the United States.

Yet its equations became the default for everyone—Mexican Americans, Puerto Ricans, Dominicans, Cubans, Central Americans, South Americans—despite the fact that none of these groups were meaningfully represented in the original data.

The American Heart Association (AHA) 2026 Scientific Statement makes this clear: “Persistent underrepresentation of Hispanic individuals in observational cohorts and clinical trials continues to limit these efforts.”

This is not a footnote. It is a structural flaw.

Why This Matters: Latino Cardiovascular Profiles Are Different.

The attached AHA statement documents a striking reality:

• Earlier onset of diabetes (diagnosed ~7 years earlier than Whites).

• Higher obesity prevalence.

• Worse hypertension control.

• Higher triglycerides in Dominican adults.

• Higher LDL-C in Cuban adults.

• Higher metabolic liver disease in Mexican adults.

• Younger age at first stroke (67 vs 73–75 in Whites).

• Younger age at heart failure diagnosis (8–9 years earlier).

These patterns do not match the Framingham profile. So when guidelines apply Framingham-derived risk equations to Latino patients, the results are often miscalibrated—sometimes overestimating risk, sometimes underestimating it, but almost always failing to capture the true picture.

The AHA statement underscores this: “Hispanic populations are highly heterogeneous… [and] aggregated data obscure differences.”

Yet our guidelines still treat Hispanic/Latino adults as a monolithic block—or worse, as interchangeable with non-Hispanic Whites.

The Consequence: Mis-Risking Millions of People.

When guidelines rely on Anglo-Saxon data:

1. Latino patients may be undertreated. Earlier diabetes, higher triglycerides, and younger stroke onset may not be fully captured by standard risk calculators.

2. Latino patients may be overtreated. The “Hispanic paradox”—lower mortality despite higher risk factor burden—means some groups may be assigned higher predicted risk than their actual event rates.

3. Precision medicine becomes impossible. Without heritage-specific data, clinicians cannot tailor prevention to Mexican, Puerto Rican, Dominican, Cuban, or Central American profiles.

4. Structural inequities worsen. Guidelines built on non-representative data reinforce disparities in diagnosis, treatment, and outcomes.

The Argument: Current CVD Guidelines Are Built on the Wrong Foundation

The core claim is straightforward:

Current cardiovascular disease guidelines are based on risk models derived from the Framingham study—an Anglo-Saxon cohort—and exclude Latino data points. As a result, they are miscalibrated for Hispanic/Latino adults and perpetuate inequities in prevention and care.

The AHA statement you provided supports this argument repeatedly:

• “Underrepresentation… limits efforts.”

• “Hispanic populations are highly heterogeneous.”

• “Disaggregated data reveal substantial differences.”

• “Risk factors emerge at earlier ages.”

These are not minor caveats. They are evidence that the foundation of our guidelines does not match the population they are meant to serve.

What Needs to Change?

To fix this, we need:

1. Latino-inclusive cohorts. Expand HCHS/SOL, MESA, and new longitudinal studies with heritage-specific sampling.

2. New risk equations. Replace Framingham-style models with tools built from multi ethnic, multi-heritage data.

3. Heritage-specific guidance. Mexican, Puerto Rican, Dominican, Cuban, Central American, and South American groups need tailored risk thresholds.

4. Structural reforms. Address language barriers, insurance gaps, environmental exposures, and immigration related stressors that shape risk.

5. Precision medicine for everyone. Genomics, multi-omics, and AI must be applied equitably—not only to populations historically overrepresented in research.

Closing Thought: Guidelines Should Reflect the People They Serve.

The AHA statement makes one thing clear: Hispanic/Latino adults are now central to the cardiovascular health of the United States.

But our guidelines still reflect Framingham, not America.

Until Latino data are fully integrated into risk prediction and guideline development, cardiovascular prevention will remain inequitable—scientifically, clinically, and morally.